The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L).
 
Kerry Anne Rogers
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Genentech; Loxo/Lilly; Pharmacyclics
Research Funding - Abbvie (Inst); Genentech (Inst); Janssen (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Xiaoxiao Lu
Employment - Janssen Scientific Affairs
Stock and Other Ownership Interests - Johnson & Johnson
 
Bruno Emond
Research Funding - Janssen Scientific Affairs (Inst)
 
Zhijie Ding
Employment - Janssen Scientific Affairs
Stock and Other Ownership Interests - Johnson & Johnson
 
Patrick Lefebvre
Research Funding - Janssen Scientific Affairs (Inst)
 
Marie-Hélène Lafeuille
Research Funding - Janssen Scientific Affairs (Inst)
 
Heena Mavani
Employment - Janssen Scientific Affairs
Stock and Other Ownership Interests - Johnson & Johnson
 
Zaina P. Qureshi
Employment - Janssen Scientific Affairs
Stock and Other Ownership Interests - Johnson & Johnson
 
Nilanjan Ghosh
Consulting or Advisory Role - Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; Beigene; Bristol-Myers Squibb; Genmab; Gilead Sciences; Incyte; Karyopharm Therapeutics; Loxo/Lilly; Novartis; Pharmacyclics/Janssen; Roche/Genentech; Seagen; TG Therapeutics
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Epizyme; Kite/Gilead; Pharmacyclics/Janssen
Research Funding - Abbvie (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Morphosys (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)